CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Open Access
- 7 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (10), 2666-2678
- https://doi.org/10.1158/0008-5472.can-20-1504
Abstract
This study demonstrates that replication checkpoint inhibitors can kill AML cells through a pathway involving AP1-mediated TNF gene activation and subsequent TP53-independent, TNFα-induced apoptosis, which can potentially be exploited clinically.Other Versions
Funding Information
- NIH (R01 CA172503)
- NIH (R01 CA190473)
- NIH (T32 GM125633)
- NIH (F30 CA213737)
This publication has 50 references indexed in Scilit:
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesThe EMBO Journal, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid CellsOnline Journal of Public Health Informatics, 2011
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content ScreeningMolecular Cancer Therapeutics, 2011
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling NetworkClinical Cancer Research, 2010
- Apoptosis: controlled demolition at the cellular levelNature Reviews Molecular Cell Biology, 2008
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007
- Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.Blood, 2006
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Induction of Apoptosis by Cancer ChemotherapyExperimental Cell Research, 2000